U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Condition:   Hemophilia B Intervention:   Biological: Coagulation Factor IX variant Sponsor:   Catalyst Biosciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hemophilia Intervention:   Drug: BAY1093884 Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionThough personalized treatment can be formalized to some extent, it is expected that medical treatment skills and management by tacit knowledge are affected in individualized treatment based on standardized treatment. Medical institutions and medical staff are the main body sharing and deploying measures to disseminate and utilize medical devices, cooperating with them can be an effective management of standardized and individualized treatment.
Source: Personalized Medicine Universe - Category: Drugs & Pharmacology Source Type: research
This study evaluated the risk of adverse outcomes of hemophilia patients who underwent THA and TKA.
Source: The Journal of Arthroplasty - Category: Orthopaedics Authors: Source Type: research
We present the first clinical description of a patient with superficial siderosis and hemophilia as the trigger of bleedings. Brain MRI was crucial for diagnosis.
Source: Interdisciplinary Neurosurgery - Category: Neurosurgery Source Type: research
AbstractDamoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII (rFVIII) product with a longer terminal half-life than non-PEGylated FVIII and rFVIII products. In the multinational ph ase II/III PROTECT VIII trial, prophylaxis with damoctocog alfa pegol reduced the likelihood of bleeding in previously treated patients aged ≥ 1...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
This report presents a newborn case with severe hemophilia A, who had a splenic hematoma presented on the second day of life with severe anemia, abdominal distention, abdominal and scrotal ecchymosis. The patient was successfully treated medically with factor VIII concentrates without splenectomy. Molecular analysis of the factor VIII gene revealed a hemizygous deletion in exon 13.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
A clinical trial on hemophilia B demonstrated efficient liver targeting with AAV5 in the presence of neutralizing antibodies.
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Editors ' Choice Source Type: research
A new plasma donation center is set to open on July 10, at 222 Gadsden Highway in Birmingham.   OctaPharma is a Lachen, Switzerland-based company that allows people to donate plasma for medical production.  “OctaPharma converts donated plasma into plasma protein products used in more than 100 countries to treat life-threatening congenital and acquired diseases such as hemophilia A and B, immune deficiency syndromes, Rh disease in newborns and burn injuries,” Dr. David J. Aarons, medical director…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
nnagl M Abstract Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is the development of neutralizing alloantibodies, known as FVIII inhibitors. HA patients who develop FVIII inhibitors have limited treatment options available to them and experience greater disease- and treatment-related burdens than HA patients without FVIII inhibitors. Emicizumab, a recently approved bispecific monoclonal antibody, mimics the function of FVIIIa by bridging FIXa and FX to restore effective hemostasis....
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Thromb Haemost Source Type: research
More News: Haemophilia | Health | Hemophilia | Legislation